West Nile Virus Infection
Conditions
Keywords
West Nile virus, WNV, Encephalitis, Meningitis, Acute Flaccid Paralysis, Monoclonal Antibody, WNND, West Nile Neuroinvasive Disease, Accidental Exposure to West Nile Virus
Brief summary
This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.
Detailed description
The objective of this study is to provide expanded access to MGAWN1; the study is not intended for subjects who are eligible for and have access to non-expanded access protocols.
Interventions
BIOLOGICALMGAWN1
Humanized monoclonal to West Nile virus. Dose=30mg/kg
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
MacroGenics
Eligibility
Sex/Gender
ALL
Age
8 Years to No maximum
Inclusion criteria
1. For West Nile Neuroinvasive Disease subjects: Have neurological signs and/or symptoms of West Nile meningitis, encephalitis, and/or acute flaccid paralysis 2. For immunocompromised subjects with suspected West Nile virus infection: * Receiving immunosuppressive treatment for any disease, such as autoimmune diseases, or transplant recipients; or * Have received organs or tissues or cells from donors likely infected with West Nile virus (as shown by serology or PCR/NAT from the donor, organs, or tissues) or * Have acquired immunodeficiency (other than from immunosuppressive treatment or from receiving infected transplants) or congenital immunodeficiency 3. For subjects with substantial exposure to West Nile virus: Exposure by any route, including percutaneous, inhalation, or mucosal exposure (such as might occur in a laboratory accident) 4. Develop signs and/or symptoms within 14 days before study enrollment
Outcome results
None listed